These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 24708856)

  • 41. Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.
    Park JE; Yuen HF; Zhou JB; Al-Aidaroos AQ; Guo K; Valk PJ; Zhang SD; Chng WJ; Hong CW; Mills K; Zeng Q
    EMBO Mol Med; 2013 Sep; 5(9):1351-66. PubMed ID: 23929599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SYK is a critical regulator of FLT3 in acute myeloid leukemia.
    Puissant A; Fenouille N; Alexe G; Pikman Y; Bassil CF; Mehta S; Du J; Kazi JU; Luciano F; Rönnstrand L; Kung AL; Aster JC; Galinsky I; Stone RM; DeAngelo DJ; Hemann MT; Stegmaier K
    Cancer Cell; 2014 Feb; 25(2):226-42. PubMed ID: 24525236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel circular RNA (hsa_circ_0000370) increases cell viability and inhibits apoptosis of FLT3-ITD-positive acute myeloid leukemia cells by regulating miR-1299 and S100A7A.
    Zhang L; Bu Z; Shen J; Shang L; Chen Y; Wang Y
    Biomed Pharmacother; 2020 Feb; 122():109619. PubMed ID: 31919040
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
    Sexauer A; Perl A; Yang X; Borowitz M; Gocke C; Rajkhowa T; Thiede C; Frattini M; Nybakken GE; Pratz K; Karp J; Smith BD; Levis M
    Blood; 2012 Nov; 120(20):4205-14. PubMed ID: 23012328
    [TBL] [Abstract][Full Text] [Related]  

  • 45. miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death.
    Bryant A; Palma CA; Jayaswal V; Yang YW; Lutherborrow M; Ma DD
    Mol Cancer; 2012 Feb; 11():8. PubMed ID: 22348345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 47. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
    Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
    Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microenvironmental hypoxia regulates FLT3 expression and biology in AML.
    Sironi S; Wagner M; Kuett A; Drolle H; Polzer H; Spiekermann K; Rieger C; Fiegl M
    Sci Rep; 2015 Nov; 5():17550. PubMed ID: 26617391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
    Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
    Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
    Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.
    Cesano A; Putta S; Rosen DB; Cohen AC; Gayko U; Mathi K; Woronicz J; Hawtin RE; Cripe L; Sun Z; Tallman MS; Paietta E
    PLoS One; 2013; 8(2):e56714. PubMed ID: 23431389
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia.
    Kim HJ; Ryu H; Choi HK; Song JY; Hwang SG; Ahn J
    Anticancer Res; 2021 Feb; 41(2):731-737. PubMed ID: 33517277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
    Skwarska A; Augustin E; Beffinger M; Wojtczyk A; Konicz S; Laskowska K; Polewska J
    Biochem Pharmacol; 2015 Jun; 95(4):238-52. PubMed ID: 25896848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
    Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
    Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
    Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
    Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TUG1 weakens the sensitivity of acute myeloid leukemia cells to cytarabine by regulating miR-655-3p/CCND1 axis.
    Zhang B; Sun YF; Zhang XM; Jiang N; Chen Q
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4940-4953. PubMed ID: 32432757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia.
    Cao T; Jiang N; Liao H; Shuai X; Su J; Zheng Q
    Sci Rep; 2019 Aug; 9(1):12209. PubMed ID: 31434952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.
    Jongen-Lavrencic M; Sun SM; Dijkstra MK; Valk PJ; Löwenberg B
    Blood; 2008 May; 111(10):5078-85. PubMed ID: 18337557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
    Russ AC; Sander S; Lück SC; Lang KM; Bauer M; Rücker FG; Kestler HA; Schlenk RF; Döhner H; Holzmann K; Döhner K; Bullinger L
    Haematologica; 2011 Dec; 96(12):1783-91. PubMed ID: 21880628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.